SG11201700066TA - Novel crystalline form of 5-chloro-n-({(5s)-2-oxo-3-[4-(5,6-dihydro-4h-[1,2,4]triazin-1-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)thiophene-2-carboxamide methanesulfonate and pharmaceutical composition containing same - Google Patents
Novel crystalline form of 5-chloro-n-({(5s)-2-oxo-3-[4-(5,6-dihydro-4h-[1,2,4]triazin-1-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)thiophene-2-carboxamide methanesulfonate and pharmaceutical composition containing sameInfo
- Publication number
- SG11201700066TA SG11201700066TA SG11201700066TA SG11201700066TA SG11201700066TA SG 11201700066T A SG11201700066T A SG 11201700066TA SG 11201700066T A SG11201700066T A SG 11201700066TA SG 11201700066T A SG11201700066T A SG 11201700066TA SG 11201700066T A SG11201700066T A SG 11201700066TA
- Authority
- SG
- Singapore
- Prior art keywords
- oxazolidin
- triazin
- thiophene
- dihydro
- oxo
- Prior art date
Links
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- DENPQNAWGQXKCU-UHFFFAOYSA-N thiophene-2-carboxamide Chemical compound NC(=O)C1=CC=CS1 DENPQNAWGQXKCU-UHFFFAOYSA-N 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
- C07D253/02—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
- C07D253/06—1,2,4-Triazines
- C07D253/065—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/KR2014/006555 WO2016010178A1 (ko) | 2014-07-18 | 2014-07-18 | 5-클로로-ｎ-({(5ｓ)-2-옥소-3-[4-(5,6-디하이드로-4h-[1,2,4]트리아진-1-일)페닐]-1,3-옥사졸리딘-5-일}메틸)티오펜-2-카르복사미드 메탄설폰산염의 신규 결정형 및 이를 포함하는 약학 조성물 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201700066TA true SG11201700066TA (en) | 2017-02-27 |
Family
ID=55078662
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201700066TA SG11201700066TA (en) | 2014-07-18 | 2014-07-18 | Novel crystalline form of 5-chloro-n-({(5s)-2-oxo-3-[4-(5,6-dihydro-4h-[1,2,4]triazin-1-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)thiophene-2-carboxamide methanesulfonate and pharmaceutical composition containing same |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US9988372B2 (ko) |
| EP (1) | EP3170819B1 (ko) |
| JP (1) | JP6450840B2 (ko) |
| KR (1) | KR102100357B1 (ko) |
| CN (2) | CN106661011B (ko) |
| AU (1) | AU2014400894B2 (ko) |
| BR (1) | BR112017000351B1 (ko) |
| CA (1) | CA2955397C (ko) |
| IL (2) | IL297649A (ko) |
| MX (1) | MX2017000409A (ko) |
| MY (1) | MY190477A (ko) |
| PH (1) | PH12017500093A1 (ko) |
| RU (1) | RU2663617C1 (ko) |
| SG (1) | SG11201700066TA (ko) |
| UA (1) | UA116182C2 (ko) |
| WO (1) | WO2016010178A1 (ko) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3789387B1 (en) * | 2018-05-02 | 2024-02-28 | Tianjin Hemay Pharmaceutical Co., Ltd. | Crystal forms of (s)-n-[5-[1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-4,6-dioxo-5,6-dihydro-4h-thieno[3,4-c]pyrrole-1-yl]acetamide |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100898361B1 (ko) * | 2008-07-03 | 2009-05-20 | 주식회사 레고켐 바이오사이언스 | Ｐ4 위치에 사이클릭 아미독심 또는 사이클릭 아미드라존기를 가지는 ＦＸａ 저해제, 이의 유도체, 제조방법 및이를 함유하는 의약 조성물 |
| KR101037052B1 (ko) * | 2009-07-08 | 2011-05-26 | 주식회사 레고켐 바이오사이언스 | 5-클로로-ｎ-(((5ｓ)-2-옥소-3-(4-(5,6-디하이드로-1,2,4-트리아진-1(4ｈ)-일)페닐)-1,3-옥사졸리딘-5-일)메틸)티오펜-2-카르복사미드 유도체의 제조방법 및 그 제조중간체 |
-
2014
- 2014-07-18 KR KR1020167035812A patent/KR102100357B1/ko active IP Right Grant
- 2014-07-18 BR BR112017000351-1A patent/BR112017000351B1/pt active IP Right Grant
- 2014-07-18 EP EP14897871.1A patent/EP3170819B1/en active Active
- 2014-07-18 MX MX2017000409A patent/MX2017000409A/es active IP Right Grant
- 2014-07-18 US US15/325,521 patent/US9988372B2/en active Active
- 2014-07-18 SG SG11201700066TA patent/SG11201700066TA/en unknown
- 2014-07-18 JP JP2017523744A patent/JP6450840B2/ja active Active
- 2014-07-18 IL IL297649A patent/IL297649A/en unknown
- 2014-07-18 CA CA2955397A patent/CA2955397C/en active Active
- 2014-07-18 RU RU2017105147A patent/RU2663617C1/ru active
- 2014-07-18 WO PCT/KR2014/006555 patent/WO2016010178A1/ko active Application Filing
- 2014-07-18 CN CN201480080661.8A patent/CN106661011B/zh active Active
- 2014-07-18 UA UAA201701494A patent/UA116182C2/uk unknown
- 2014-07-18 CN CN201910687566.9A patent/CN110407827B/zh active Active
- 2014-07-18 MY MYPI2016704816A patent/MY190477A/en unknown
- 2014-07-18 AU AU2014400894A patent/AU2014400894B2/en active Active
-
2017
- 2017-01-13 PH PH12017500093A patent/PH12017500093A1/en unknown
- 2017-01-17 IL IL250168A patent/IL250168A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN106661011A (zh) | 2017-05-10 |
| NZ727829A (en) | 2021-01-29 |
| KR102100357B1 (ko) | 2020-04-13 |
| US9988372B2 (en) | 2018-06-05 |
| EP3170819B1 (en) | 2019-07-10 |
| KR20170023003A (ko) | 2017-03-02 |
| CA2955397C (en) | 2019-01-08 |
| AU2014400894A1 (en) | 2017-02-02 |
| RU2663617C1 (ru) | 2018-08-07 |
| IL250168A0 (en) | 2017-03-30 |
| BR112017000351B1 (pt) | 2022-10-25 |
| CA2955397A1 (en) | 2016-01-21 |
| CN106661011B (zh) | 2020-01-10 |
| JP6450840B2 (ja) | 2019-01-09 |
| MY190477A (en) | 2022-04-22 |
| US20170152251A1 (en) | 2017-06-01 |
| CN110407827A (zh) | 2019-11-05 |
| EP3170819A4 (en) | 2018-05-16 |
| PH12017500093A1 (en) | 2017-05-22 |
| BR112017000351A2 (pt) | 2017-11-07 |
| CN110407827B (zh) | 2023-05-23 |
| MX2017000409A (es) | 2017-05-01 |
| WO2016010178A1 (ko) | 2016-01-21 |
| JP2017521500A (ja) | 2017-08-03 |
| UA116182C2 (uk) | 2018-02-12 |
| AU2014400894B2 (en) | 2018-04-19 |
| EP3170819A1 (en) | 2017-05-24 |
| IL297649A (en) | 2022-12-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL236455A0 (en) | Pharmaceutical dosage forms containing 5-chloro-n-({s5)-2-oxo-3-[4-(3-oxo-4-morpholinyl)phenyl]-3,1-oxazolidin-5-yl]methyl)-2 - Thiopencarboxamide | |
| IL210483A0 (en) | Pharmaceutical compositions comprising 5-chlooro-n-({(5s)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophencarboxamid | |
| MY176244A (en) | Crystalline salt form of (s)-(2-(6-chloro-7-methyl-1h-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1-yl)(5-methoxy-2-(2h-1,2,3-triazol-2-yl)phenyl)methanone as orexin receptor antagonist | |
| PH12016500988A1 (en) | Crystalline form of (s)-(2-(6-chloro-7-methyl-1h-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1 -yl)(5-methoxy-2-(2h-1,2,3-triazol-2-yl)phenyl)methanone and its use as orexin receptor antagonists | |
| EP3262039A4 (en) | Process for the preparation of amorphous (1s)-1,5-anhvdro-1-[3-[[5-(4 fluorophennyl)-2-thienyl]methvl]-4-methylphenyl]-d-glucitol and its polymorphs thereof | |
| IL255718B (en) | Crystalline form of the compound (s)-3-{4-[5-(2-cyclopentyl-6-methoxy-pyridin-4-yl)-[4,2,1]oxadiazol-3-yl]-2-ethyl- 6-methyl-phenoxy}-propane-2,1-diol | |
| IL252744A0 (en) | Solid forms comprising (1E,4E)-2-amino-N,N-dipropyl-8-(4-(pyrrolidine-1-carbonyl)phenyl)-3H-benzo[bi]azepine-4-carboxamide, their preparations and their uses | |
| IL250168A0 (en) | Crystalline form of 5 – chloro –n ( { (5s) – 2 – oxo – 3 – [ 4 – ( 5,6 – dihydro – 4h – [ 1,2,4 ] triazin-1-yl) phenyl] – 1, 3-oxazolidine-5-yl}methyl)thiophene-2-an innovative carboxamide and pharmaceutical preparations containing it | |
| WO2014141067A3 (en) | Process for the preparation of oxazolidinone derivatives | |
| IL249248A0 (en) | Non-aqueous crystalline form of 6-{2-[1-(6-methyl-3-pyridazinyl)-4-piperidinyl]ethoxy}-3-ethoxy-2,1-benzaisoxazole | |
| MX2016013875A (es) | Ingrediente activo (i) que contiene una composicion y metodo para prepararla. | |
| PH12015501625A1 (en) | Aldehyde derivative of substitute oxazolidinones | |
| WO2012080184A3 (de) | Flüssige, oral applizierbare pharmazeutische zusammensetzungen enthaltend 5-chlor-n-({(5s)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophencarboxamid | |
| IL263299A (en) | Crystalline form of (r)-4-(5-(cyclopropylethynyl)isoxazol-3-yl)-n-hydroxy-2-methyl-2-(methylsulfonyl)butanamide as an antibacterial agent | |
| EP2451803A4 (en) | PROCESS FOR THE PREPARATION OF 5-CHLORO-N - ({(5S) -2-OXO-3- [4- (5,6-DIHYDRO-4H- [1,2,4] TRIAZIN-1-YL) DERIVATIVE PHENYL] -1,3-OXAZOLIDIN-5-YL} METHYL) THIOPHEN-2-CARBOXAMIDE AND INTERMEDIATE USED THEREFOR | |
| TH1601000138A (th) | เกลือชนิดใหม่ของ 3-[(3-{[4-(4-มอร์โฟลินิลเมทธิล)-1h-ไพร์รอล-2-อิล]เมทธิลลีน}-2-ออกโซ-2,3-ไดไฮโดร-1h-อินดอล-5-อิล)เมทธิล]-1,3-ไธอะโซลิดีน-2,4-ไดโอน การเตรียมของมันและสูตรผสมที่มีมันประกอบอยู่ | |
| CU20080051A7 (es) | Nueva forma polimórfica y la forma amorfa de 5-cloro-n-({(5s)-2-oxo-3-[4-(3-oxo-4-morfolinil)-fenil]-1,3-oxazolidin-5-il}-metil)-2-tiofenocarboxamida |